Capstone Investment Advisors
PRCT icon

Capstone Investment Advisors’s Procept Biorobotics PRCT Stock Holding History

Capstone Investment Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,798
Closed -$680K – 2028
2025
Q2 		$680K Buy
+11,798
New +$667K ﹤0.01% 998
2021
Q4 		– Sell
-5,347
Closed -$204K – 2048
2021
Q3 		$204K Buy
+5,347
New +$205K ﹤0.01% 1688

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capstone Investment Advisors's PRCT Position: Q3 2025 in Review

Capstone Investment Advisors sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 11,798 shares — an estimated $680K sold.

Capstone Investment Advisors first reported a position in PRCT in Q3 2021 and held it in 2 quarters. The position peaked at $680K in Q2 2025. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • Capstone Investment Advisors reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 11,798 Procept Biorobotics shares in Q3 2025, an estimated $680K.
  • Capstone Investment Advisors first reported a position in Procept Biorobotics in Q3 2021 and held it in 2 quarters.
  • Capstone Investment Advisors's Procept Biorobotics position peaked at $680K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on Capstone Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.